Bevacizumab biosimilar (Intas Pharmaceuticals)

贝伐珠单抗生物类似药（Intas Pharmaceuticals）

Report date: 2022/03/16 17:43:29

Base Information

Drug NameBevacizumab biosimilar (Intas Pharmaceuticals)
Drug Alias NameRecombinant immunoglobulin G1 monoclonal antibody biosimilarBevatasINTP-24
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar
Mechanisms of ActionAngiogenesis inhibitorsVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Global Approved IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2017/10/04
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesIntas Biopharmaceuticals
China Registration ClassN/A

Develop Information

Active CompaniesIntas Biopharmaceuticals
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsCarcinoma, Non-Small-Cell Lung +[9] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XC07
Related LinksN/A